

Frank Ruschitzka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/465211/publications.pdf>

Version: 2024-02-01

363
papers

91,042
citations

3515

90
h-index

300

291
g-index

370
all docs

370
docs citations

370
times ranked

71012
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. <i>Cardiovascular Research</i> , 2023, 118, 3374-3385.	1.8	10
2	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1352-1360.	0.8	26
3	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 312-318.	1.0	9
4	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	1.5	8
5	Right ventricular only pacing for cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 70-71.	0.7	2
6	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2022, 118, 2385-2396.	1.8	14
7	TNF α induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF α antibodies. <i>Cardiovascular Research</i> , 2022, 118, 254-266.	1.8	13
8	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. <i>American Heart Journal</i> , 2022, 247, 33-41.	1.2	8
9	Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis. <i>ESC Heart Failure</i> , 2022, 9, 1186-1194.	1.4	2
10	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
11	Adult T-cells impair neonatal cardiac regeneration. <i>European Heart Journal</i> , 2022, 43, 2698-2709.	1.0	19
12	Predictors of left atrial fibrosis in patients with atrial fibrillation referred for catheter ablation. <i>Cardiology Journal</i> , 2022, 29, 413-422.	0.5	7
13	Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 611-621.	1.4	10
14	Diagnosis of acute heart failure in CT pulmonary angiography: feasibility and accuracy. <i>European Radiology</i> , 2022, , 1.	2.3	3
15	Assessment of Artificial Intelligence in Echocardiography Diagnostics in Differentiating Takotsubo Syndrome From Myocardial Infarction. <i>JAMA Cardiology</i> , 2022, 7, 494.	3.0	18
16	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 667-684.	2.5	15
17	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	1.0	14
18	Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. <i>European Heart Journal</i> , 2022, 43, 2756-2766.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española De Cardiología, 2022, 75, 523.e1-523.e114.	0.6	40
20	Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	2.9	10
21	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. Cardiovascular Research, 2021, 117, 2275-2288.	1.8	13
22	Deletion of fibroblast activation protein provides atheroprotection. Cardiovascular Research, 2021, 117, 1060-1069.	1.8	20
23	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. American Journal of Medicine, 2021, 134, 482-489.	0.6	53
24	Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from Spanish flu 1918/1919 in Switzerland to Coronavirus disease 2019. Journal of Pathology: Clinical Research, 2021, 7, 135-143.	1.3	29
25	Vascular endothelial growth factor D is a biomarker of fluid overload in haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 529-536.	0.4	5
26	Exercise intolerance from spiroergometry to transdiaphragmatic myocardial punch biopsy: a case report of isolated cardiac sarcoidosis. European Heart Journal - Case Reports, 2021, 5, yta121.	0.3	0
27	Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2021, 14, 135-144.	1.1	19
28	SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine, 2021, 63, 103182.	2.7	93
29	Familial dilated cardiomyopathy associated with a novel heterozygous RYR2 early truncating variant. Cardiology Journal, 2021, 28, 173-175.	0.5	7
30	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 445-452.	0.4	5
31	Impact of Genetic Variant Reassessment on the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy Based on the 2010 Task Force Criteria. Circulation Genomic and Precision Medicine, 2021, 14, e003047.	1.6	13
32	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	1.4	8
33	Pre-transplant Social Adaptability Index and clinical outcomes in renal transplantation: The Swiss Transplant Cohort study. Clinical Transplantation, 2021, 35, e14218.	0.8	1
34	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
35	Outcome of Patients With Severe Aortic Stenosis and Normal Coronary Arteries Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 143, 89-96.	0.7	0
36	Improving 1-year mortality prediction in ACS patients using machine learning. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 855-865.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
38	TNF- α antagonism rescues the effect of ageing on stroke: Perspectives for targeting inflammation in ageing. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13600.	1.7	17
39	Accuracy of dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease in patients with reduced ejection fraction. <i>Imaging</i> , 2021, 13, 61-68.	0.3	0
40	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
41	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
42	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e014059.	1.6	18
43	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
44	Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1858-1871.	2.9	86
45	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. <i>ESC Heart Failure</i> , 2021, 8, 4955-4967.	1.4	26
46	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
47	Long-term follow-up after cardiac resynchronization therapy-optimization in a real-world setting: A single-center cohort study. <i>Cardiology Journal</i> , 2021, 28, 728-737.	0.5	2
48	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
49	Treatment of Advanced Heart Failure—Focus on Transplantation and Durable Mechanical Circulatory Support. <i>Heart Failure Clinics</i> , 2021, 17, 697-708.	1.0	2
50	Use of induction therapy in pediatric heart transplant recipients in Switzerland – Analysis of the Swiss national database. <i>Transplant Immunology</i> , 2021, 68, 101443.	0.6	0
51	The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 487-496.	0.4	3
52	Absenteeism and presenteeism in healthcare workers due to respiratory illness. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 268-273.	1.0	14
53	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	1.0	71
54	Efficacy of Catheter Ablation for Atrial Arrhythmias in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy—A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4962.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Postprocedural Troponin Elevation and Mortality After Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2021, 10, e020739.	1.6	2
56	Professor Willibald Maier. <i>European Heart Journal</i> , 2021, 42, 881-881.	1.0	0
57	581â€fVentricularâ€ arterial coupling derived from proximal aortic stiffness and aerobic capacity across the heart failure spectrum. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
58	Pulmonary vein isolation using ablation index vs. CLOSE protocol with a surround flow ablation catheter. <i>Europace</i> , 2020, 22, 84-89.	0.7	24
59	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving bloodâ€ brain barrier integrity: a translational study. <i>European Heart Journal</i> , 2020, 41, 1575-1587.	1.0	54
60	Management of allergy transfer upon solid organ transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 834-843.	2.6	8
61	Evaluation of kidney function throughout the heart failure trajectoryâ€ position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 584-603.	2.9	213
62	Sexâ€ and ageâ€ related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€ Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	2.9	81
63	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€ based analysis of the InterTAK Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 330-337.	2.9	24
64	Effects of hemodialysis on blood volume, macro- and microvascular function. <i>Microvascular Research</i> , 2020, 129, 103958.	1.1	1
65	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	2.9	47
66	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	1.1	34
67	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€ glucose coâ€ transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	2.9	66
68	Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. <i>Atherosclerosis</i> , 2020, 314, 58-62.	0.4	213
69	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€ Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€ Oncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	184
70	Postischemic Administration of IL-1Î± Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke. <i>Circulation</i> , 2020, 142, 187-189.	1.6	18
71	Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. <i>EClinicalMedicine</i> , 2020, 25, 100449.	3.2	155
72	Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a longâ€ term retrospective cohort study. <i>ESC Heart Failure</i> , 2020, 7, 2773-2783.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Prognostic value of texture analysis from cardiac magnetic resonance imaging in patients with Takotsubo syndrome: a machine learning based proof-of-principle approach. Scientific Reports, 2020, 10, 20537.	1.6	9
74	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	6.3	425
75	Blood Pressure-Lowering Therapy. Handbook of Experimental Pharmacology, 2020, , 1.	0.9	1
76	Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. American Heart Journal, 2020, 228, 98-108.	1.2	11
77	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	2.9	101
78	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92
79	Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac Decompensation. Journal of Clinical Medicine, 2020, 9, 2689.	1.0	8
80	Integration of a palliative approach into heart failure care: a <scp>European Society of Cardiology Heart Failure Association</scp> position paper. European Journal of Heart Failure, 2020, 22, 2327-2339.	2.9	88
81	Clinical benefits and safety of renal denervation in severe arterial hypertension: A long-term follow-up study. Journal of Clinical Hypertension, 2020, 22, 1854-1864.	1.0	7
82	Multimodal Multiparametric Three-dimensional Image Fusion in Coronary Artery Disease: Combining the Best of Two Worlds. Radiology: Cardiothoracic Imaging, 2020, 2, e190116.	0.9	3
83	Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Medicine, 2020, 18, 103.	2.3	40
84	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	1.0	49
85	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. American Journal of Transplantation, 2020, 20, 2876-2882.	2.6	102
86	Plasma testosterone and arrhythmic events in male patients with arrhythmogenic right ventricular cardiomyopathy. ESC Heart Failure, 2020, 7, 1547-1559.	1.4	12
87	Management of heart failure patients with <scp>COVID</scp>-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	2.9	95
88	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardio-<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardio-<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020, 22, 1315-1341.	2.9	364
89	Epidemiology, pathophysiology and contemporary management of cardiogenic shock: Aa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	2.9	244
90	Effect of daily 2000 IU versus 800 IU vitamin D on blood pressure among adults age 60 years and older: a randomized clinical trial. American Journal of Clinical Nutrition, 2020, 112, 527-537.	2.2	8

#	ARTICLE	IF	CITATIONS
91	Myocardial edema in COVID-19 on cardiac MRI. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 730-732.	0.3	14
92	Electron microscopy of SARS-CoV-2: a challenging task – Authors' reply. <i>Lancet, The</i> , 2020, 395, e100.	6.3	64
93	How to diagnose heart failure with preserved ejection fraction: the HFA – PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	2.9	193
94	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology – Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	1.4	23
95	Sodium – glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	2.9	100
96	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association of the European Society of Cardiology (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	2.9	234
97	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. <i>Radiotherapy and Oncology</i> , 2020, 152, 203-207.	0.3	59
98	The Heart Failure Association Atlas: rationale, objectives, and methods. <i>European Journal of Heart Failure</i> , 2020, 22, 638-645.	2.9	23
99	Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. <i>American Heart Journal</i> , 2020, 223, 34-43.	1.2	13
100	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	2.9	50
101	Unravelling the interplay between hyperkalaemia, renin – angiotensin – aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC – HFA – EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
102	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC – EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
103	COVID-19 illness and Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 512-514.	1.9	127
104	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <i>Transplant Infectious Disease</i> , 2020, 22, e13289.	0.7	11
105	Age-Related Variations in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1869-1877.	1.2	42
106	Endothelial cell infection and endotheliitis in COVID-19. <i>Lancet, The</i> , 2020, 395, 1417-1418.	6.3	5,100
107	Acute heart and brain failure: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-8.	0.3	1
108	Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy. <i>Open Heart</i> , 2020, 7, e001152.	0.9	8

#	ARTICLE	IF	CITATIONS
109	Fiftieth anniversary of the first heart transplantation in Switzerland in the context of the worldwide history of heart transplantation. <i>Swiss Medical Weekly</i> , 2020, 150, w20192.	0.8	1
110	Impact of a nationwide COVID-19 lockdown on acute coronary syndrome referrals. <i>Cardiology Journal</i> , 2020, 27, 633-635.	0.5	8
111	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27
112	Pulmonary vein isolation using a higher power shorter duration CLOSE protocol with a surround flow ablation catheter. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2199-2204.	0.8	48
113	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010881.	1.6	63
114	Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum?. <i>European Journal of Heart Failure</i> , 2019, 21, 988-997.	2.9	20
115	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011194.	1.6	27
116	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. <i>Circulation</i> , 2019, 139, 413-415.	1.6	75
117	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	2.9	20
118	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019, 40, 3297-3317.	1.0	944
119	Contemporary Presentation and Management of Valvular Heart Disease. <i>Circulation</i> , 2019, 140, 1156-1169.	1.6	281
120	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	2.9	182
121	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	2.9	490
122	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 844-851.	2.9	91
123	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	2.9	446
124	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
125	Acute heart failure congestion and perfusion status: impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170
126	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. <i>European Heart Journal</i> , 2019, 40, 2142-2151.	1.0	79

#	ARTICLE	IF	CITATIONS
127	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224
128	Age-dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients. <i>Physiological Reports</i> , 2019, 7, e14021.	0.7	1
129	The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. <i>European Journal of Heart Failure</i> , 2019, 21, 402-424.	2.9	202
130	Takotsubo Recurrence. <i>Journal of the American College of Cardiology</i> , 2019, 73, 982-984.	1.2	53
131	Epicardial adipose tissue volume is associated with adverse outcomes after transcatheter aortic valve replacement. <i>International Journal of Cardiology</i> , 2019, 286, 29-35.	0.8	14
132	Improving Selection of Mitraclip Candidates in Advanced Chronic Heart Failure: Look Right to Predict Right. <i>Journal of Cardiac Failure</i> , 2019, 25, 312-313.	0.7	5
133	Cardiovascular magnetic resonance T2* mapping for structural alterations in hypertrophic cardiomyopathy. <i>European Journal of Radiology Open</i> , 2019, 6, 78-84.	0.7	14
134	Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction. <i>Physiological Reports</i> , 2019, 7, e14222.	0.7	6
135	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	2.9	42
136	Pulsatile arterial blood pressure mimicking aortic valve opening during continuous-flow LVAD support: a case report. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 219.	0.4	4
137	Interleukin-1 β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. <i>Journal of Clinical Medicine</i> , 2019, 8, 2072.	1.0	70
138	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	1.2	39
139	The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 137-155.	2.9	605
140	Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 3-13.	2.9	84
141	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	1.0	123
142	The future of continuing medical education: the roles of medical professional societies and the health care industry. <i>European Heart Journal</i> , 2019, 40, 1720-1727.	1.0	11
143	Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment. <i>Cardiac Failure Review</i> , 2019, 5, 140-146.	1.2	85
144	Outcome of inter-hospital transfer of patients on extracorporeal membrane oxygenation in Switzerland. <i>Swiss Medical Weekly</i> , 2019, 149, w20054.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Baseline Predictors of Renal Failure in Transcatheter Aortic Valve Implantation. <i>Journal of Invasive Cardiology</i> , 2019, 31, E289-E297.	0.4	2
146	Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1021-1030.	2.9	31
147	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—“who is doing what to whom and how?”. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	2.9	107
148	Cardiac manifestation of polyarteritis nodosa. <i>European Heart Journal</i> , 2018, 39, 2603-2603.	1.0	4
149	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018, 20, 842-850.	2.9	17
150	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
151	Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	1.4	50
152	Retinal microvascular dysfunction in heart failure. <i>European Heart Journal</i> , 2018, 39, 47-56.	1.0	91
153	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	2.9	128
154	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018, 39, 17-25.	1.0	111
155	Successful support of biventricular heart failure patients by new EXCOR® Adult pumps with bileaflet valves: a prospective study. <i>Clinical Research in Cardiology</i> , 2018, 107, 413-420.	1.5	17
156	The year in cardiology 2017: heart failure. <i>European Heart Journal</i> , 2018, 39, 832-839.	1.0	5
157	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2018, 20, 1081-1099.	2.9	57
158	Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. <i>International Journal of Cardiology</i> , 2018, 258, 206.	0.8	0
159	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1325-1333.	1.2	14
160	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	2.9	317
161	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	2.9	239
162	Mitral interventions in heart failure: time to deliver on the promise. <i>European Journal of Heart Failure</i> , 2018, 20, 609-611.	2.9	3

#	ARTICLE	IF	CITATIONS
163	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35.	1.0	426
164	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 332-341.	2.9	69
165	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1615-1633.	2.9	74
166	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 314-340.	0.7	254
167	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	1.0	171
168	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Trial. <i>Journal of Cardiac Failure</i> , 2018, 23, 101-108.	2.9	73
169	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14,964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018, 39, 4277-4284.	1.0	189
170	Retinal microvascular dysfunction in hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1523-1531.e2.	0.6	22
171	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	2.9	555
172	The effect of oxygen in Sirt3-mediated myocardial protection: a proof-of-concept study in cultured cardiomyoblasts. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 102-112.	1.0	0
173	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. <i>European Heart Journal</i> , 2018, 39, 2032-2046.	1.0	972
174	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. <i>European Heart Journal</i> , 2018, 39, 2047-2062.	1.0	521
175	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	1.2	224
176	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
177	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	20
178	Pericardial effusion unrelated to surgery is a predictor of mortality in heart transplant patients. <i>Cardiology Journal</i> , 2018, 25, 714-721.	0.5	3
179	Effectiveness of cardiovascular implantable electronic devices with a defibrillator component therapy according to ventricular assist device implant strategy: data from the PCHF-VAD registry. <i>Cardiologia Croatica</i> , 2018, 13, 358-360.	0.0	0
180	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). <i>European Heart Journal</i> , 2017, 38, ehw387.	1.0	58

#	ARTICLE	IF	CITATIONS
181	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , 2017, 38, ehw506.	1.0	22
182	Reply to Letter to the Editor "Endothelial dysfunction in Takotsubo syndrome". <i>International Journal of Cardiology</i> , 2017, 234, 102.	0.8	0
183	Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. <i>Europace</i> , 2017, 19, 1848-1854.	0.7	10
184	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , 2017, 19, 449-456.	2.9	19
185	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	13.9	257
186	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1242-1254.	2.9	339
187	True Anemia-Red Blood Cell Volume Deficit-in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	16
188	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017, 19, 821-836.	2.9	252
189	Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 775-780.	0.6	5
190	BK Polyomavirus-Specific 9mer CD8 T Cell Responses Correlate With Clearance of BK Viremia in Kidney Transplant Recipients: First Report From the Swiss Transplant Cohort Study. <i>American Journal of Transplantation</i> , 2017, 17, 2591-2600.	2.6	52
191	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1574-1585.	2.9	568
192	Prognostic value of long-term blood pressure changes in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 837-842.	2.9	32
193	The year in cardiology 2016: heart failure. <i>European Heart Journal</i> , 2017, 38, ehw638.	1.0	1
194	A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1036-1042.	2.9	142
195	SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2017, 238, 205-216.	1.0	12
196	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	2.9	115
197	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	1.0	5,142
198	3D fusion of coronary CT angiography and CT myocardial perfusion imaging: Intuitive assessment of morphology and function. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 437-443.	0.7	6

#	ARTICLE	IF	CITATIONS
199	heartfailurematters.org™, an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. European Journal of Heart Failure, 2017, 19, 1447-1454.	2.9	21
200	Endothelial dysfunction in cardiovascular disease and Flammer syndrome—similarities and differences. EPMA Journal, 2017, 8, 99-109.	3.3	68
201	Effect of cardiac resynchronization therapy in patients with diabetes randomized in <sc>EchoCRT</sc>. European Journal of Heart Failure, 2017, 19, 80-87.	2.9	5
202	Rationale for and design of the <sc>TRUEâ€œAHF</sc> trial: the effects of ularitide on the shortâ€œterm clinical course and longâ€œterm mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	2.9	31
203	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) Tj ETQq1 1 0.784314 rgBT JOverload 38, 3282-3292.	1.0	86
204	Cocoa, Blood Pressure, and Vascular Function. Frontiers in Nutrition, 2017, 4, 36.	1.6	68
205	"Real world" experience in Cardiac Resynchronization Therapy at a Swiss Tertiary Care Center. Swiss Medical Weekly, 2017, 147, w14425.	0.8	2
206	The subcutaneous implantable cardioverter defibrillator in daily clinical practice. Swiss Medical Weekly, 2017, 147, w14518.	0.8	1
207	European Society of Cardiology Heart Failure Longâ€œTerm Registry (<sc>ESCâ€œHFâ€œLT</sc>): 1â€œyear followâ€œup outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	2.9	538
208	Henry Krum, Pioneering Heart Failure Researcher. European Journal of Heart Failure, 2016, 18, 125-126.	2.9	0
209	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 859-868.	2.9	36
210	ECG Criteria to Differentiate Between Takotsubo (Stress) Cardiomyopathy and Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	111
211	HeartFailureNews, new inEJHF. European Journal of Heart Failure, 2016, 18, 451-451.	2.9	0
212	Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections. BMC Infectious Diseases, 2016, 16, 321.	1.3	15
213	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
214	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal, 2016, 37, 2823-2829.	1.0	136
215	Differences in the Clinical Profile and Outcomes of Typical and Atypical Takotsubo Syndrome. JAMA Cardiology, 2016, 1, 335.	3.0	189
216	Finerenone in heart failure: walking a fine line. European Heart Journal, 2016, 37, 2115-2117.	1.0	9

#	ARTICLE	IF	CITATIONS
217	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-blind, Randomized, Placebo-controlled Trial. <i>Clinical Cardiology</i> , 2016, 39, 285-290.	0.7	8
218	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 8-27.	2.9	835
219	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	2.9	455
220	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
221	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
222	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
223	Survival, quality of life and impact of right heart failure in patients with acute cardiogenic shock treated with ECMO. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2016, 45, 409-415.	0.8	14
224	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. <i>New England Journal of Medicine</i> , 2016, 375, 2519-2529.	13.9	607
225	Heart failure specialization in Europe. <i>European Journal of Heart Failure</i> , 2016, 18, 347-349.	2.9	9
226	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2016, 18, 1096-1105.	2.9	160
227	Positive emotions and Takotsubo syndrome: "happy heart" or "Diagoras" syndrome?. <i>European Heart Journal</i> , 2016, 37, 2821-2822.	1.0	8
228	The year in cardiology 2015: heart failure. <i>European Heart Journal</i> , 2016, 37, 437-441.	1.0	2
229	Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. <i>Kidney International</i> , 2016, 89, 927-938.	2.6	37
230	Peri-infarct pacing to prevent left reverse remodelling: an unvalidated concept?. <i>European Heart Journal</i> , 2016, 37, 494-495.	1.0	1
231	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2016, 37, 49-59.	1.0	43
232	Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system. <i>Cardiology Journal</i> , 2016, 23, 384-392.	0.5	8
233	Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. <i>Swiss Medical Weekly</i> , 2016, 146, w14295.	0.8	7
234	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	2.9	315

#	ARTICLE	IF	CITATIONS
235	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	2.9	60
236	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	1.0	105
237	Reply to Cunha et al. <i>Clinical Infectious Diseases</i> , 2015, 61, 1894-1895.	2.9	0
238	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	0.7	22
239	Polymorphisms and Invasive Mold Infections After Solid Organ Transplant: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 619-622.	2.9	91
240	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2015, 36, 1983-1989.	1.0	65
241	The year in cardiology: heart failure 2014. <i>European Heart Journal</i> , 2015, 36, 421-424.	1.0	3
242	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015, 373, 929-938.	13.9	1,827
243	EJ's new impact factor of 15.2: a global strategy is paying off. <i>European Heart Journal</i> , 2015, 36, 2763-2766.	1.0	0
244	Recurrent Clotting of a Continuous-Flow Right Ventricular Assist Device – Repeated Thrombolysis With Two Different Protocols. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 1614-1617.	0.6	5
245	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	1.0	902
246	The Year in Cardiology 2013: heart failure. <i>European Heart Journal</i> , 2014, 35, 470-473.	1.0	12
247	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. <i>New England Journal of Medicine</i> , 2014, 370, 578-581.	13.9	0
248	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	1.4	38
249	Superresponse to Cardiac Resynchronization Therapy. <i>Circulation</i> , 2014, 130, 87-90.	1.6	50
250	Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. <i>European Heart Journal</i> , 2014, 35, 1051-1060.	1.0	52
251	Surviving 20 Years After Heart Transplantation: A Success Story. <i>Annals of Thoracic Surgery</i> , 2014, 97, 499-504.	0.7	24
252	New devices in heart failure: an European Heart Rhythm Association report: Developed by the European Heart Rhythm Association; Endorsed by the Heart Failure Association. <i>Europace</i> , 2014, 16, 109-128.	0.7	62

#	ARTICLE	IF	CITATIONS
253	Takotsubo cardiomyopathy: still much more to learn. <i>Heart</i> , 2014, 100, 1804-1812.	1.2	75
254	Is the panic about beta-blockers in perioperative care justified?. <i>European Heart Journal</i> , 2014, 35, 2442-2444.	1.0	32
255	Long-Term Performance of Modern Coronary Sinus Leads in Cardiac Resynchronization Therapy. <i>Indian Pacing and Electrophysiology Journal</i> , 2014, 14, 112-120.	0.3	5
256	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	1.4	1
257	Comprehensive cardiac resynchronization therapy optimization in the real world. <i>Cardiology Journal</i> , 2014, 21, 316-324.	0.5	9
258	FastTrack: a key success factor for the <i>European Heart Journal</i> . <i>European Heart Journal</i> , 2014, 35, 1983-90.	1.0	0
259	The wealth of nations and the dissemination of cardiovascular research. <i>International Journal of Cardiology</i> , 2013, 169, 190-195.	0.8	7
260	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
261	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. <i>New England Journal of Medicine</i> , 2013, 369, 1395-1405.	13.9	688
262	Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. <i>International Journal of Cardiology</i> , 2013, 168, 2453-2461.	0.8	86
263	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
264	Allograft vasculopathy vs. coronary artery disease: comparison by optical coherence tomography. <i>European Heart Journal</i> , 2013, 34, 137-137.	1.0	7
265	The <i>European Heart Journal</i> on the move: can scientific publishing be further improved?. <i>European Heart Journal</i> , 2013, 34, 409-415.	1.0	4
266	Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. <i>European Heart Journal</i> , 2013, 34, 3515-3524.	1.0	132
267	Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 1414-1423.	1.0	35
268	Donor-specific anti-HLA antibodies detected by Luminex: predictive for short-term but not long-term survival after heart transplantation. <i>Transplant International</i> , 2013, 26, 1097-1107.	0.8	22
269	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
270	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	1.0	2,176

#	ARTICLE	IF	CITATIONS
271	Response to Letters Regarding Article, "Statins and the Risk of Cancer After Heart Transplantation", <i>Circulation</i> , 2013, 127, e442.	1.6	0
272	Destination therapy "time for a paradigm change in heart failure therapy. <i>Swiss Medical Weekly</i> , 2013, 143, w13729.	0.8	11
273	Psoriasis and atherosclerosis: two plaques, one syndrome?. <i>European Heart Journal</i> , 2012, 33, 1989-1991.	1.0	54
274	Statins and the Risk of Cancer After Heart Transplantation. <i>Circulation</i> , 2012, 126, 440-447.	1.6	64
275	Working together in cardiovascular prevention: the common mission of the <i>European Heart Journal</i> and the <i>European Journal of Preventive Cardiology</i> . <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1217-1226.	0.8	4
276	Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. <i>European Heart Journal</i> , 2012, 33, 1589-1597.	1.0	70
277	Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure. <i>Circulation</i> , 2012, 126, 2962-2975.	1.6	111
278	The <i>European Heart Journal</i> and the <i>European Journal of Heart Failure</i> : partners in scientific publishing. <i>European Journal of Heart Failure</i> , 2012, 14, 1075-1082.	2.9	6
279	Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. <i>European Heart Journal</i> , 2012, 33, 2172-2180.	1.0	104
280	The best of the <i>European Heart Journal</i> : look back with pride. <i>European Heart Journal</i> , 2012, 33, 1161-1171.	1.0	10
281	Torcetrapib impairs endothelial function in hypertension. <i>European Heart Journal</i> , 2012, 33, 1615-1624.	1.0	75
282	Reconstituted HDL in Acute Coronary Syndromes. <i>Cardiovascular Therapeutics</i> , 2012, 30, e51-7.	1.1	36
283	The challenge of nonresponders to cardiac resynchronization therapy: Lessons learned from oncology. <i>Heart Rhythm</i> , 2012, 9, S14-S17.	0.3	9
284	From abstract to impact in cardiovascular research: factors predicting publication and citation. <i>European Heart Journal</i> , 2012, 33, 3034-3045.	1.0	66
285	2012 HFA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	ARTICLE	IF	CITATIONS
289	Cocoa, Blood Pressure, and Vascular Function. <i>Current Hypertension Reports</i> , 2012, 14, 279-284.	1.5	21
290	Evidence for improvement in survival with antihypertensive combination treatment. <i>Journal of Hypertension</i> , 2011, 29, S9-S14.	0.3	5
291	Peripartum Cardiomyopathy With Cardiogenic Shock: Recovery After Prolactin Inhibition and Mechanical Support. <i>Annals of Thoracic Surgery</i> , 2011, 91, 274-276.	0.7	19
292	NTa€proBNP Provides Incremental Prognostic Information in Cardiac Outpatients With and Without Echocardiographic Findings. <i>Clinical Cardiology</i> , 2011, 34, 183-188.	0.7	11
293	Is There a Link Between Angiotensin Receptor Blockers and Cancer?. <i>Current Hypertension Reports</i> , 2011, 13, 5-7.	1.5	0
294	In search of improved therapies for acute heart failure. <i>Nature Reviews Cardiology</i> , 2011, 8, 9-10.	6.1	2
295	Beyond dyspnoea as an endpoint in acute heart failure trials. <i>European Heart Journal</i> , 2011, 32, 1442-1445.	1.0	15
296	Isolated right ventricular ballooning syndrome: a new variant of transient cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1821-1821.	1.0	27
297	Cyclosporine CO- versus C2-monitoring over three years in maintenance heart transplantation. <i>Swiss Medical Weekly</i> , 2011, 141, w13149.	0.8	4
298	Darusentan in Resistant Hypertension: Lost in Translation. <i>Current Hypertension Reports</i> , 2010, 12, 1-3.	1.5	2
299	Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye. <i>Current Hypertension Reports</i> , 2010, 12, 33-38.	1.5	11
300	Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease. <i>Circulation</i> , 2010, 122, 1789-1796.	1.6	146
301	Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 231-240.	1.0	7
302	Happy birthday <i>European Heart Journal</i> : in 30 years, from Cinderella to centre stage. <i>European Heart Journal</i> , 2010, 31, 1945-1950.	1.0	14
303	Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. <i>European Heart Journal</i> , 2010, 31, 1477-1485.	1.0	74
304	Association of intraventricular mechanical dyssynchrony with response to cardiac resynchronization therapy in heart failure patients with a narrow QRS complex. <i>European Heart Journal</i> , 2010, 31, 3054-3062.	1.0	42
305	Angiotensin receptor blockers: baseline therapy in hypertension?. <i>European Heart Journal</i> , 2009, 30, 2427-2430.	1.0	28
306	Cardiac resynchronization therapy in patients with a narrow QRS. <i>Current Heart Failure Reports</i> , 2009, 6, 49-56.	1.3	25

#	ARTICLE	IF	CITATIONS
307	The BEAUTIFUL study: Is heart rate reduction a new therapeutic principle?. Current Hypertension Reports, 2009, 11, 45-47.	1.5	0
308	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American Heart Journal, 2009, 157, 606-612.	1.2	115
309	Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thrombosis Research, 2009, 123, 460-465.	0.8	43
310	Vitamin D and hypertension. Current Hypertension Reports, 2008, 10, 49-51.	1.5	5
311	Auricall [®] . A new device for a non-invasive, wireless, continuous monitoring of oxygen saturation and heart rate in patients with heart failure. International Journal of Cardiology, 2008, 129, 141-143.	0.8	2
312	Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis. Circulation, 2008, 117, 2262-2269.	1.6	108
313	Response to Letter Regarding Article, "Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis". Circulation, 2008, 118, .	1.6	0
314	Darusentan: a new perspective for treatment of resistant hypertension?. Expert Opinion on Investigational Drugs, 2008, 17, 1255-1263.	1.9	7
315	Cardiovascular risk of cyclooxygenase ² inhibitors and traditional non ^{steroidal} anti ^{inflammatory} drugs. Annals of Medicine, 2007, 39, 18-27.	1.5	32
316	Dark Chocolate Improves Coronary Vasomotion and Reduces Platelet Reactivity. Circulation, 2007, 116, 2376-2382.	1.6	215
317	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
318	Painful lessons: COX-2 inhibitors, NSAIDs, and hypertension. Current Hypertension Reports, 2007, 9, 41-44.	1.5	6
319	Endothelin-receptor antagonists in arterial hypertension: Further indications?. Current Hypertension Reports, 2007, 9, 59-65.	1.5	6
320	Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 349, 597-603.	1.0	11
321	Novel anti-inflammatory drugs in hypertension. Nephrology Dialysis Transplantation, 2006, 21, 859-864.	0.4	11
322	The Blue Man. Circulation, 2006, 113, e63.	1.6	12
323	C-reactive protein influences shear stress-dependent platelet adhesion in patients with familial hypercholesterolemia and coronary artery disease undergoing LDL apheresis. Thrombosis and Haemostasis, 2006, 96, 540-2.	1.8	3
324	"Class effect" [™] amongst cardiac drugs: term of convenience or pharmacological reality?. International Journal of Clinical Practice, 2005, 60, 2-5.	0.8	1

#	ARTICLE	IF	CITATIONS
325	Cardiovascular Effects of Coffee: Is It a Risk Factor?. <i>Progress in Cardiovascular Nursing</i> , 2005, 20, 65-69.	0.5	38
326	Anti-inflammatory strategies in hypertension: Focus on COX-1 and COX-2. <i>Current Hypertension Reports</i> , 2005, 7, 52-60.	1.5	5
327	Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH 2 Kinase Phosphorylation. <i>Circulation</i> , 2005, 111, 1685-1689.	1.6	111
328	Selective COX-2 Inhibitors and Renal Injury in Salt-Sensitive Hypertension. <i>Hypertension</i> , 2005, 45, 193-197.	1.3	61
329	Are selective cyclo-oxygenase 2 inhibitors safe after coronary artery bypass grafting surgery?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 504-505.	3.3	2
330	Coffee Blunts Mental Stress-Induced Blood Pressure Increase in Habitual but Not in Nonhabitual Coffee Drinkers. <i>Hypertension</i> , 2005, 46, 521-526.	1.3	47
331	To the Heart of the Matter. <i>Circulation</i> , 2005, 112, 941-945.	1.6	24
332	Simvastatin improves endothelial function in patients with rheumatoid arthritis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 461-464.	1.2	99
333	Shear stress-dependent platelet function after LDL cholesterol apheresis. <i>Thrombosis Research</i> , 2004, 113, 395-398.	0.8	15
334	Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. <i>American Journal of Hypertension</i> , 2004, 17, S243.	1.0	0
335	Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2004, 364, 347-354.	6.3	315
336	Lyme Carditis. <i>Cardiology in Review</i> , 2004, 12, 185-187.	0.6	15
337	Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. <i>FASEB Journal</i> , 2003, 17, 259-261.	0.2	70
338	Dysfunctional Baroreflex Regulation of Sympathetic Nerve Activity in Patients With Vasovagal Syncope. <i>Circulation</i> , 2003, 107, 1620-1625.	1.6	70
339	Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease. <i>Circulation</i> , 2003, 107, 405-409.	1.6	367
340	Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced Hypertension. <i>Circulation</i> , 2003, 108, 2308-2311.	1.6	127
341	Coffee Acutely Increases Sympathetic Nerve Activity and Blood Pressure Independently of Caffeine Content. <i>Circulation</i> , 2002, 106, 2935-2940.	1.6	214
342	High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men. <i>Circulation</i> , 2002, 105, 1399-1402.	1.6	425

#	ARTICLE	IF	CITATIONS
343	Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ETA) Receptor Blockade in Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 2666-2672.	1.6	221
344	Mental Stress Induces Prolonged Endothelial Dysfunction via Endothelin-A Receptors. <i>Circulation</i> , 2002, 105, 2817-2820.	1.6	297
345	Anti-Tumor Necrosis Factor- α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis. <i>Circulation</i> , 2002, 106, 2184-2187.	1.6	559
346	Vasopeptidase inhibition: Effective blood pressure control for vascular protection. <i>Current Hypertension Reports</i> , 2002, 4, 78-84.	1.5	7
347	Endothelin antagonists and heart failure. <i>Current Hypertension Reports</i> , 2002, 4, 85-92.	1.5	15
348	Vasopeptidase Inhibitors. <i>Circulation</i> , 2001, 104, 1856-1862.	1.6	224
349	EARTH: Endothelin Receptor Antagonist Trial in Heart Failure. <i>Cardiology</i> , 2001, 1, 294-298.	0.3	3
350	Vasopeptidase Inhibitors: A New Class of Drugs. <i>Cardiology</i> , 2001, 1, 96-102.	0.3	1
351	Endothelin 1 Type A Receptor Antagonism Prevents Vascular Dysfunction and Hypertension Induced by 11 β -Hydroxysteroid Dehydrogenase Inhibition. <i>Circulation</i> , 2001, 103, 3129-3135.	1.6	51
352	Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2146-2151.	0.4	19
353	Vasopeptidase inhibitors' concepts and evidence. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1532-1535.	0.4	12
354	Aldosterone Receptor Antagonism Normalizes Vascular Function in Liquorice-Induced Hypertension. <i>Hypertension</i> , 2001, 37, 801-805.	1.3	78
355	Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2280-2287.	3.0	32
356	Tissue Endothelin-Converting Enzyme Activity Correlates With Cardiovascular Risk Factors in Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 1086-1092.	1.6	33
357	Acute heart transplant rejection due to Saint John's wort. <i>Lancet</i> , The, 2000, 355, 548-549.	6.3	682
358	Endothelial Dysfunction in Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 953-962.	3.0	42
359	Different Effects of Thrombin Receptor Activation on Endothelium and Smooth Muscle Cells of Human Coronary Bypass Vessels. <i>Circulation</i> , 1997, 95, 1870-1876.	1.6	49
360	Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. <i>Kidney International</i> , 1995, 47, 795-801.	2.6	34

#	ARTICLE	IF	CITATIONS
361	Cardiac amyloidosis. Cardiovascular Medicine(Switzerland), 0, , .	0.1	1
362	Cardiac amyloidosis. Cardiovascular Medicine(Switzerland), 0, , .	0.1	0
363	Soluble ST2 â€” a new biomarker in heart failure. Cardiovascular Medicine(Switzerland), 0, , .	0.1	8